Free Trial

Globus Medical (GMED) Stock Price, News & Analysis

+0.65 (+0.98%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
959,877 shs
Average Volume
1.34 million shs
Market Capitalization
$9.09 billion
P/E Ratio
Dividend Yield
Price Target

Globus Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.64 Rating Score
2.0% Upside
$68.50 Price Target
Short Interest
6.64% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.86mentions of Globus Medical in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$5.94 M Sold Last Quarter
Proj. Earnings Growth
From $2.82 to $3.27 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.46 out of 5 stars

Medical Sector

106th out of 921 stocks

Surgical & Medical Instruments Industry

16th out of 91 stocks

GMED stock logo

About Globus Medical Stock (NYSE:GMED)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

GMED Stock Price History

GMED Stock News Headlines

Globus Medical (NYSE:GMED) Upgraded to Overweight by Piper Sandler
Truist Financial Keeps Their Hold Rating on Globus Medical (GMED)
Globus Medical Reports First Quarter 2024 Results
Globus Medical A earnings preview: what to expect
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
11 Analysts


Net Income
$122.87 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.57 billion
Cash Flow
$3.66 per share
Book Value
$28.98 per share


Free Float
Market Cap
$9.09 billion
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

GMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMED shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price target for 2024?

11 Wall Street analysts have issued 1-year target prices for Globus Medical's stock. Their GMED share price targets range from $53.00 to $85.00. On average, they anticipate the company's stock price to reach $68.50 in the next twelve months. This suggests a possible upside of 2.0% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2024?

Globus Medical's stock was trading at $53.29 at the start of the year. Since then, GMED stock has increased by 26.0% and is now trading at $67.15.
View the best growth stocks for 2024 here

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest in April. As of April 30th, there was short interest totaling 8,990,000 shares, an increase of 19.7% from the April 15th total of 7,510,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is presently 8.0 days.
View Globus Medical's Short Interest

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our GMED earnings forecast

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings data on Tuesday, May, 7th. The medical device company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.17. The medical device company had revenue of $606.67 million for the quarter, compared to analysts' expectations of $586.82 million. Globus Medical had a net margin of 3.51% and a trailing twelve-month return on equity of 8.82%. The firm's revenue for the quarter was up 119.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.53 EPS.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of 2.750-2.850 for the period, compared to the consensus EPS estimate of 2.690. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.09%), Janus Henderson Group PLC (5.66%), Bank of New York Mellon Corp (2.23%), Champlain Investment Partners LLC (1.85%), Burgundy Asset Management Ltd. (1.83%) and William Blair Investment Management LLC (1.65%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Leslie V Norwalk.
View institutional ownership trends

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GMED) was last updated on 5/23/2024 by Staff

From Our Partners